Verastem, Inc. (VSTM) Reaches $3.26 After 5.00% Down Move; Shorts at VIVENDI ORD SHARES (VIVEF) Raised By 10.04%

February 15, 2018 - By wolcottdaily

The stock of Verastem, Inc. (NASDAQ:VSTM) is a huge mover today! The stock decreased 1.21% or $0.04 during the last trading session, reaching $3.26. About 129,089 shares traded. Verastem, Inc. (NASDAQ:VSTM) has risen 71.53% since February 15, 2017 and is uptrending. It has outperformed by 54.83% the S&P500.The move comes after 5 months negative chart setup for the $164.75 million company. It was reported on Feb, 15 by Barchart.com. We have $3.10 PT which if reached, will make NASDAQ:VSTM worth $8.24M less.

VIVENDI ORD SHARES (OTCMKTS:VIVEF) had an increase of 10.04% in short interest. VIVEF’s SI was 306,900 shares in February as released by FINRA. Its up 10.04% from 278,900 shares previously. With 4,700 avg volume, 65 days are for VIVENDI ORD SHARES (OTCMKTS:VIVEF)’s short sellers to cover VIVEF’s short positions. The stock increased 0.62% or $0.17 during the last trading session, reaching $27.65. About 1,900 shares traded. Vivendi SA (OTCMKTS:VIVEF) has 0.00% since February 15, 2017 and is . It has underperformed by 16.70% the S&P500.

Among 10 analysts covering Verastem (NASDAQ:VSTM), 5 have Buy rating, 0 Sell and 5 Hold. Therefore 50% are positive. Verastem had 29 analyst reports since September 9, 2015 according to SRatingsIntel. The stock of Verastem, Inc. (NASDAQ:VSTM) has “Buy” rating given on Thursday, September 17 by H.C. Wainwright. Oppenheimer maintained Verastem, Inc. (NASDAQ:VSTM) on Friday, June 16 with “Buy” rating. Jefferies maintained the stock with “Hold” rating in Monday, June 26 report. The firm has “Buy” rating given on Wednesday, December 13 by H.C. Wainwright. The stock of Verastem, Inc. (NASDAQ:VSTM) has “Buy” rating given on Monday, June 26 by Oppenheimer. Cantor Fitzgerald upgraded the shares of VSTM in report on Wednesday, September 6 to “Overweight” rating. On Monday, September 28 the stock rating was downgraded by TH Capital to “Neutral”. The company was maintained on Monday, September 25 by Cantor Fitzgerald. The firm has “Hold” rating by Cantor Fitzgerald given on Tuesday, September 29. The rating was downgraded by Raymond James to “Outperform” on Tuesday, September 29.

Investors sentiment increased to 1.4 in Q3 2017. Its up 0.23, from 1.17 in 2017Q2. It improved, as 6 investors sold Verastem, Inc. shares while 19 reduced holdings. 19 funds opened positions while 16 raised stakes. 12.96 million shares or 49.25% more from 8.68 million shares in 2017Q2 were reported. Grp Inc One Trading Lp has invested 0% of its portfolio in Verastem, Inc. (NASDAQ:VSTM). Wells Fargo And Mn invested in 0% or 19,951 shares. Raymond James Service Advsrs Incorporated stated it has 17,830 shares or 0% of all its holdings. Virtu Fincl Ltd Limited Liability Company holds 0% of its portfolio in Verastem, Inc. (NASDAQ:VSTM) for 73,787 shares. Dimensional Fund Ltd Partnership reported 561,969 shares. Massachusetts-based Acadian Asset Mgmt Limited Liability Corporation has invested 0% in Verastem, Inc. (NASDAQ:VSTM). Art Advsr Ltd reported 190,018 shares. National Bank & Trust Of Mellon invested in 30,786 shares. Highbridge Cap Mgmt Ltd Liability Corporation has invested 0.01% in Verastem, Inc. (NASDAQ:VSTM). Bankshares Of America De reported 5,011 shares. Millennium Management Limited Liability Co has invested 0% of its portfolio in Verastem, Inc. (NASDAQ:VSTM). Geode Capital Mgmt Ltd Limited Liability Company has 0% invested in Verastem, Inc. (NASDAQ:VSTM) for 225,127 shares. Advisory Ltd Liability stated it has 0.01% of its portfolio in Verastem, Inc. (NASDAQ:VSTM). Point72 Asset Mngmt Limited Partnership holds 0.03% in Verastem, Inc. (NASDAQ:VSTM) or 1.40M shares. Artal Group Sa stated it has 750,000 shares.

Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing drugs for the treatment of cancer. The company has market cap of $164.75 million. The Company’s programs target the focal adhesion kinase and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. It currently has negative earnings. The Company’s lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds.

Analysts await Verastem, Inc. (NASDAQ:VSTM) to report earnings on March, 22. They expect $-0.43 EPS, down 34.38% or $0.11 from last year’s $-0.32 per share. After $-0.61 actual EPS reported by Verastem, Inc. for the previous quarter, Wall Street now forecasts -29.51% EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: